Kanamycin-Pos (Kanamycin Monosulphate)

Kanamycin binds to the bacterial 30S ribosomal subunit, causing misreading of messenger RNA and halting protein synthesis. This bactericidal action eliminates susceptible Gram‑negative and some Gram‑positive organisms that cause eye infections.

The dosing regimen for Kanamycin-Pos is determined by the prescribing clinician based on the severity of the infection, patient age and ocular condition. Healthcare professionals set the number of drops, frequency and duration of therapy.

Kanamycin’s pregnancy category is unknown, and systemic absorption from ocular use is low but not negligible. It should be used during pregnancy or lactation only if the potential benefit justifies any potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kanamycin‑Pos belongs to the aminoglycoside class, offering broad‑spectrum activity especially against Gram‑negative organisms. Compared with fluoroquinolone eye drops, kanamycin may have a lower risk of developing resistance but carries a higher potential for ototoxicity if systemic absorption occurs.

Kanamycin‑Pos should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from light, moisture and extreme temperature fluctuations to maintain sterility and potency.

The medication is applied as eye drops. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., every 2–4 hours), and the total duration of treatment, typically ranging from several days to a week.

Serious risks include systemic ototoxicity and nephrotoxicity if significant absorption occurs, severe allergic reactions such as anaphylaxis, and rare but serious ocular complications like corneal ulceration or vision loss. Immediate medical attention is required if these occur.

Patients with a known hypersensitivity to kanamycin, other aminoglycosides, or any component of the formulation should avoid using Kanamycin‑Pos. It is also contraindicated in individuals with severe renal impairment unless closely monitored by a specialist.